KHB(SZ:002022) Sou Hu Cai Jing·2025-05-20 08:39Group 1 - The core business of the company is the research, production, and sales of in vitro diagnostic reagents and medical testing instruments [1] - As of March 31, 2025, the number of shareholders is 42,590, a decrease of 1,756 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] - The latest financial report for Q1 2025 shows a revenue of 388 million yuan, a year-on-year decrease of 12.50%, and a net profit of -53,259,784.78 yuan, a year-on-year decrease of 84.79%, with a gross profit margin of 37.39% [1] Group 2 - The company's current price-to-earnings ratio (TTM) is -4.68, and the price-to-book ratio is 0.95, with a total market capitalization of 3.112 billion yuan [2] - The industry average price-to-earnings ratio is 49.51, while the industry median is 36.17, indicating that the company is significantly below industry averages [2] - The company has received various honors, including the National Science and Technology Progress Second Prize and recognition as a National High-tech Enterprise [1]